Hepatitis C virus genotype 3 is cytopathic to hepatocytes: Reversal of hepatic steatosis after sustained therapeutic response

Hepatology

Volumn 36, Issue 5, 2002, Pages 1266-1272

  Kumar, Dinesh ^a   Farrell, Geoffrey C ^a   Fung, Caroline ^b   George, Jacob ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b WESTMEAD HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTIVIRUS AGENT; RIBAVIRIN;

ADULT; AGED; ALCOHOL CONSUMPTION; ANTIVIRAL ACTIVITY; ARTICLE; BODY WEIGHT; CHRONIC HEPATITIS; CLINICAL ARTICLE; COMPUTER ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; FATTY LIVER; FEMALE; GENETIC RISK; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMAGE ANALYSIS; LIVER BIOPSY; LIVER CELL; LOGISTIC REGRESSION ANALYSIS; MALE; MORPHOMETRICS; PREDICTION; PRIORITY JOURNAL; QUANTITATIVE DIAGNOSIS; SCORING SYSTEM; SUSTAINED VIRAL RESPONSE;

EID: 0036830436     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1053/jhep.2002.36370     Document Type: Article

References (23)

1. Hourigan LF, Macdonald GA, Purdie D, Whitehall VH, Shorthouse C, Clouston A, Powell EE. Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis. Hepatology 1999;29:1215-1219.
2. Adinolfi LE, Gambardella M, Andreanan A, Tripodi MF, Utili R, Ruggiero G. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology 2001;33:1358-1364.
3. Chitturi S, Farrell GC. Etiopathogenesis of nonalcoholic steatohepatitis. Semin Liver Dis 2001;21:27-41.
4. Hui JM, Kench J, Farrell GF, Lin R, Samarasinghe D, Liddle C, George J. Genotype-specific mechanisms for hepatic steatosis in chronic hepatitis C infection. J Gastroenterol Hepatol 2002;17:873-881.
5. Rubbia-Brandt L, Quadri R, Abid K, Giostra E, Male PJ, Mentha G, Spahr L, et al. Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3. J Hepatol 2000;33:106-115.
6. Serfaty L, Andreani T, Giral P, Carbonell N, Chazouilleres O, Poupon R. Hepatitis C virus induced hypobetalipoproteinemia: A possible mechanism for steatosis in chronic hepatitis C. J Hepatol 2001;34:428-434.
7. Castera L, Hezode C, Bastie A, Roudot-Thoraval F, Zafrani E-S, Pawlotsky J-M, Dhumeaux D. Effect of antiviral therapy treatment on the evolution of steatosis in patients with chronic hepatitis C (CHC) and serial liver biopsies [Abstract]. Hepatology 2000;32(Suppl):363A.
8. Kaba S, Durra U, Byth K, Crewe EB, Khan MH, Coverdale SA, Lin R, et al. Molecular epidemiology of hepatitis C in Australia. J Gastroenterol Hepatol 1998;13:914-920.
9. Lin R, Roach E, Zimmerman M, Strasser S, Farrell GC. Interferon alfa-2b for chronic hepatitis C: Effects of dose increment and duration of treatment on response rates. Results of the first multicentre Australian trial. Australia Hepatitis C Study Group. J Hepatol 1995;23:487-496.
10. Farrell G, Cooksley WG, Dudley FJ, Watson K. Efficacy and tolerance of a 6-month treatment course of daily interferon-alpha 2a for chronic hepatitis C with cirrhosis. The Australian Hepatitis C Study Group. J Viral Hepatol 1997;4:317-323.
11. Farrell GC, Bacon BR, Goldin RD. Lymphoblastoid interferon alfa-n1 improves the long-term response to a 6-month course of treatment in chronic hepatitis C compared with recombinant interferon alfa-2b: results of an international randomized controlled trial. Clinical Advisory Group for the Hepatitis C Comparative Study. Hepatology 1998;27:1121-1127.
12. Scheuer PJ. Classification of chronic viral hepatitis: A need for reassessment. J Hepatol 1991;13:372-374.
13. Brunt EM, Janney CG, DiBisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: A proposal for grading and staging the histological lesions. Am J Gastroenterol 1999;24:2467-2474.
14. Rubbia-Brandt L, Giostra E, Mentha G, Quadri R, Negro F. Expression of liver steatosis in hepatitis C virus infection and pattern of response to alpha-interferon. J Hepatol 2001;35:307.
15. Petersen KF, West AB, Reuben A, Rothman DL, Shulman GI. Noninvasive assessment of hepatic triglyceride content in humans with 13C nuclear magnetic resonance spectroscopy. Hepatology 1996;24:114-117.
16. Fujie H, Yotsuyanagi H, Moriya K, Shintani Y, Tsutsumi T, Takayama T, Makuuchi M, et al. Steatosis and intrahepatic hepatitis C virus in chronic hepatitis. J Med Virol 1999;59:141-145.
17. Lerat H, Honda M, Beard MR, Loesch K, Sun J, Yang Y, Okuda M, et al. Steatosis and liver cancer in transgenic mice expressing the structural and non-structural proteins of hepatitis C virus. Gastroenterology 2002;122:352-365.
18. Okuda M, Li K, Beard M, Showalter L, Scholle F, Lemon SM, Weinman SA. Mitochondrial injury, oxidative stress, and antioxidant gene expression are induced by hepatitis C virus core protein. Gastroenterology 2002;122:366-375.
19. Angello V, Abel G, Elfahal M, Knight G, Zhang Q-X. Hepatitis C virus and other Flaviviridae viruses enter cells via low density lipoprotein receptor. Proc Natl Acad Sci U S A 1999;96:12766-12771.
20. Shi ST, Polyak SJ, Tu H, Taylor DR, Gretch DR, Lai M. Hepatitis C virus NS5A colocalizes with the core protein on lipid droplets and interacts with apolipoproteins. Virology 2002;292:198-210.
21. Perlemuter G, Sabile A, Letteron P, Vona G, Topilco A, Chretien Y, Koike K, et al. Hepatitis C virus core protein inhibits microsomal triglyceride transfer protein activity and very low density lipoprotein secretion: A model of viral-related steatosis. FASEB J 2002;16:85-94.
22. Moriya K, Yotsuyanagi H, Shintani Y, Fujie H, Ishibashi K, Matsuura Y, Miyamura T, et al. Hepatitis C virus core protein induces hepatic steatosis in transgenic mice. J Gen Virol 1997;78:1527-1531.
23. Barba G, Harper F, Harada T, Kohara M, Goulinet S, Matsurra Y, Eder G, et al. Hepatitis C virus core protein shows a cytoplasmic localization and associates to cellular lipid storage droplets. Proc Natl Acad Sci U S A 1997;94:1200-1205.